PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...
From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments in bladder cancer frequently have made news over the past 12 months. The ...
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
Radical cystectomy continues to have an important role in the management of recurrent high-grade NMIBC, according to results from the CISTO study. The CISTO study assessed patient-important outcomes ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback